Company news

Natera, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Natera Reports Second Quarter 2020 Financial Results

August 4, 2020

Natera Announces Second Quarter 2020 Earnings Conference Call

July 28, 2020

Natera Announces Clinical Data at ESMO GI Supporting Personalized ctDNA Testing for Oligometastatic Colorectal Cancer (CRC) Patients

July 6, 2020

Natera Expands Lab Footprint With State-Of-The-Art Facility in Austin, Texas

June 21, 2020

Natera Announces First Patient Enrollments in Both CIRCULATE-Japan and BESPOKE CRC Trials Using Signatera™ MRD Testing

June 17, 2020

Natera Launches Quantification Technique to Enhance Prospera™ Test Precision; Initiates PEDAL Study for New Insights

May 31, 2020

Natera Announces New Prospera™ Data at ATC Showcasing Innovation in Cell-Free DNA

May 25, 2020

Natera Announces New Data at ASCO Highlighting Utility of Personalized MRD Monitoring

May 18, 2020

Natera and Illumina Settle Patent Dispute

May 17, 2020

Natera Reports First Quarter 2020 Financial Results

May 5, 2020

Natera Announces Achievement of Key Recruitment Milestones in ProActive Study and Success in Prospera™ Early Access Program

May 3, 2020

Natera Announces First Quarter 2020 Earnings Conference Call

April 28, 2020

Natera Prices $250 Million Convertible Senior Notes Due 2027

April 12, 2020

Natera to Offer $250 Million Convertible Senior Notes Due 2027

April 12, 2020

Natera Provides Remote Access to Tests Without Requiring Live Office Visits

March 18, 2020

Natera Receives Favorable Medicare Reimbursement Pricing for Prospera™

March 2, 2020

Natera Reports Fourth Quarter and Year 2019 Financial Results

February 25, 2020

Natera Announces Fourth Quarter and Fiscal 2019 Earnings Conference Call

February 18, 2020

Natera Announces New Early Priority Date cfDNA Patent, Files Suit Against CareDx

January 12, 2020

Natera Launches BESPOKE CRC Study to Evaluate Outcomes in 1,000 Signatera(TM) Patients with Stage II-III Colorectal Cancer

January 8, 2020

Natera Announces Achievement of $55 Million In Pharma Contracts and Issuance of New Oncology Patents

January 5, 2020

Natera Receives Final Medicare Coverage for Prospera(TM) Organ Transplant Rejection Assessment Test

December 18, 2019

Natera Reports Third Quarter 2019 Financial Results

November 5, 2019

Natera Announces Third Quarter 2019 Earnings Conference Call

October 29, 2019

Natera Appoints Rowan Chapman to its Board of Directors

August 28, 2019

Natera to Webcast Live Presentation at the Baird 2019 Global Healthcare Conference

August 27, 2019

Medicare Issues Positive Draft Local Coverage Determination for Natera's Signatera(TM) MRD Test in Colorectal Cancer

August 21, 2019

Natera Reports Second Quarter 2019 Financial Results

August 6, 2019

Natera Announces Second Quarter 2019 Earnings Conference Call

July 30, 2019

Natera Announces First Quarter 2019 Earnings Conference Call

May 1, 2019

Natera Announces Plans to Commercialize Tumor Whole Exome Sequencing from Plasma

April 9, 2019

← Newer news releases

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 57 decks. Every deck is listed under its year.